Kornimate/medical-research-clean huggingface dataset:
post discharge human milk fortifier in preterm infants

Conditions: Infant, Low Birth Weight

Summary: the purpose of this study is to determine whether low birth weight (lbw) infants fed human milk (hm)supplemented with a specially designed powdered human milk fortifier until 12 weeks after hospital discharge will have better growth and neurodevelopment than infants fed hm alone.

consensus exists in the literature that a significant proportion of low birth weight (lbw, \<1800 g) infants leave hospital with overt signs of under-nutrition (eg. growth retardation). recent evidence from randomized control trials suggest that provision of nutrient-enriched feeding to formula-fed premature infants after hospital discharge improves their growth, accretion of lean body mass and bone mineral content compared to infants fed a standard term formula. while available data suggest an advantage of human milk feeding after hospital discharge, experimental evidence on which to base guidelines to enrich, or not to enrich, human milk (hm) are notably absent.

Eligibility criteria:
inclusion criteria: * birth weight between 750-1800 g * gestational age at birth between 26 and 32 weeks * singleton or twin birth (for twins to be eligible, both must meet eligibility criteria) * small for gestational age or appropriate for gestational age * ≥ 80% energy received from human milk in the previous three days * ≥ 25% of human milk consumed orally in the previous three days * mother agrees to exclusively feed her infant human nilk after discharge * if so randomized, parents agree to supplement \~1/2 or the human milk provided to her infant as powdered human milk fortifier for 12 weeks after hospital discharge * subject's parents have voluntarily signed an informed consent form exclusion criteria: * serious congenital or chromosomal anomalies that will affect growth * grade iii or iv periventricular/intraventricular hemorrhage * received steroids within 14 days o randomization * asphyxia (hypoxia or ischemia) es evident by severe and permanent neurological data * maternal incapacity, including maternal cocaine or alcohol abuse dring pregnancy, or concurrent, or mother or infant has tested positive for hiv * principal residence of study family outside gta * mother unable to verbally communicate in english * a single feeding must be fortified \> 24 kcal/oz or \>50% of feeds need to be fortified

Keywords: low birth weight fortified human milk breastfeeding infants growth
a study to evaluate effectiveness and safety of ponatinib in patients with bcr-abl positive all in standard clinical practice in europe - "poseidon"

Conditions: BCR-ABL Positive Acute Lymphoblastic Leukemia

Summary: the purpose of this study is to evaluate the effectiveness and safety of ponatinib (iclusig®) in patients with bcr-abl positive acute lymphoblastic leukemia (all) in standard clinical practice in europe.


Eligibility criteria:
inclusion criteria: * adult patients with bcr-abl (ph+) positive all who are initiating iclusig®, or for whom iclusig® was initiated after january 2015. * patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures. exclusion criteria: * patients previously treated with investigational ponatinib. * patients who are pregnant and/or breastfeeding. * concurrent treatment with another tyrosine kinase inhibitor for ph+all.

Keywords: acute lymphoblastic leukemia ponatinib tyrosine kinase inhibitor
effects of lp28 on immunity enhancement in the elderly

Conditions: Common Cold; Immunity; Probiotic

Summary: due to the increasing attention on aging-related health issues, this study focuses on the elderly population as participants. the aim is to investigate whether supplementation with lactobacillus plantarum lp28 can effectively enhance immunity, reduce the frequency and severity of common cold infections, and ultimately promote overall health in the elderly.


Eligibility criteria:
inclusion criteria: * those who had symptoms of common cold or tonsillitis at least twice in the past year. exclusion criteria: * people who have liver, kidney, immune, or neoplastic diseases diagnosed by doctor. * people with mental illnesses such as schizophrenia or depression. * people who have allergic rhinitis. * people who have a current condition of drug or alcohol dependence. * any person is deemed inappropriate by the researcher for the clinical trial.
a study of patient reported outcomes after stereotactic radiosurgical rhizotomy for trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: the investigators know little about how patients feel following radiosurgery treatment of trigeminal neuralgia. patient satisfaction may ultimately be one of the most important outcome measures for an individual patient; however, this has not been adequately assessed or followed. multiple questions remain unanswered, including whether there is a correlation between patient satisfaction, the level of their current pain score, and the presence and degree of facial numbness, a possible side effect after radiosurgery. therefore, the goal of this study is to gather this information from the patients who received radiosurgery for trigeminal neuralgia at stanford and evaluate post-treatment patient satisfaction, the degree of facial numbness, and current pain score. this data will help the investigators understand outcomes that are important for patient satisfaction following treatment of a chronic pain syndrome.


Eligibility criteria:
inclusion criteria: * all of the patients since 2000 who have undergone stereotactic radiosurgical rhizotomy at stanford for treatment of trigeminal neuralgia. exclusion criteria: * none
a study to evaluate the safety and pharmacokinetic profile of a p38 inhibitor (ph-797804) in subjects with rheumatoid arthritis who are also taking methotrexate

Conditions: Arthritis, Rheumatoid

Summary: the hypothesis of this study is that the p38 inhibitor (ph-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.


Eligibility criteria:
inclusion criteria: * adult with ra for at least 6 months * stable weekly dosage of oral methotrexate 12.5- 25 mg/week exclusion criteria: * severe, progressive and/or uncontrolled other disease * chronic or recent serious infection; current infection * concomitant use of ra therapy other than methotrexate with some exceptions

Keywords: arthritis, rheumatoid
the role of circdennd4c in epithelial ovarian cancer

Conditions: Ovarian Cancer

Summary: circular rnas (circrnas), a newly discovered type of endogenous noncoding rnas \[8\], are involved in the regulation of various biological functions. they act by sponging off certain micrornas (mirnas) and play a role in the pathogenesis of many diseases, including cancers \[9-11\]. in addition, circrnas are not com- monly degraded by rna enzymes present in body flu- ids \[8\], and most of them possess expression specificity at the tissue, cell, and developmental stage level \[12,13\]. thus, they can be ideal clinica

epithelial oc (eoc), the most common form of oc, accounts for 90% of all oc cases \[2\]. eoc has the highest mortality among all gynecologic tumors and poses a serious threat to women's life \[3\].herefore, early clinical diagnosis is crucial. commonly used laboratory indicators for oc diagnosis

Eligibility criteria:
inclusion criteria: - patients at south egypt cancer institute and recently diagnosed ovarian cancer patients 2. patients not went to surgery. exclusion criteria: * . patients receive any anti-cancer therapy. 2. patients diagnosed with other concomitante cancer or chronic disease
molecular characterization of patients affected by williams syndrome and autism.

Conditions: Williams Beuren Syndrome; Autism Spectrum Disorder

Summary: williams beuren syndrome (wbs) is a multiple malformations/intellectual disability (id) syndrome caused by 7q11.23 microdeletion and clinically characterized by a typical neurocognitive profile including excessive talkativeness and social disinhibition, often defined as "overfriendliness" and "hypersociability". wbs is generally considered as the polar opposite phenotype to autism spectrum disorder (asd). surprisingly, the prevalence of asd has been reported to be significantly higher in wbs (12%) than in general population (1%). this study aims to investigate the molecular basis of the peculiar association of asd and wbs. the investigator performed chromosomal microarray analysis and whole exome sequencing in six patients presenting with wbs and asd, in order to evaluate the possible presence of chromosomal or gene variants considered as pathogenic.


Eligibility criteria:
inclusion criteria: * the diagnosis of wbs was confirmed by fluorescent in situ hybridization. * all patients met formal asd criteria * written informed consent exclusion criteria: * none

Keywords: williams beuren syndrome autism spectrum disorder
determinants of diabetes remission after gastric bypass surgery

Conditions: Type 2 Diabetes Mellitus

Summary: longitudinal study of beta cell function up to 2 years after gbp surgery. evaluation of the role of endogenous glucagon-like peptide-1 (glp-1).

the increased prevalence of obesity and type 2 diabetes (t2dm) has resulted in a surge in the number of patients seeking surgical weight loss. gastric bypass surgery (gbp) results in 30-40% body weight loss with resolution of t2dm in 40-80% of cases. the mechanisms by which t2dm improves after gbp are unclear. glycemic control occurs long before significant weight loss, suggesting that the nature of the procedure, rather than the weight loss, is responsible for the t2dm improvement. recent data have singled out the role of the gut hormones known as incretins in diabetes improvement after gbp. the current proposal will study 1) whether the short and long term change in the gut hormone incretins after gbp results in improved insulin secretion in response to the administration of oral and iv glucose, in patients with diabetes undergoing gbp surgery; 2) the factors responsible for diabetes remission - or lack of - after gbp. the investigators wish to apply our finding to define better surgical outcome on diabetes.

Eligibility criteria:
inclusion criteria: * patients with a wide range of t2dm (duration, treatment modalities and control, in or not in remission) and scheduled for gbp surgery * blood pressure is under at least moderate control \<160/100 mmhg * patients can be on dyslipidemia medications but need fasting triglyceride \< 600 mg/dl * patients without recent (last 6 months) history of cardiovascular disease (cvd) * bmi \> 35 and \< 55 kg/m2 prior to gbp surgery exclusion criteria: * active cancer * unstable angina * recent stroke * current therapy that may affect glucose metabolism such as glucocorticoids, hiv medications, etc * active infection * kidney failure * severe liver dysfunction * severe respiratory or cardiac failure * history of allergic reaction to exendin 9-39 * history of pancreatitis, history of cholelithiasis, history of alcoholism * presence of high triglyceride levels (\>600 ng/dl) * pregnancy (a pregnancy test will be done prior to enrollment and prior to each procedure in all premenopausal women)

Keywords: type 2 diabetes mellitus gastric bypass surgery exendin9
postoperative pain relief after major abdominal gynecological surgery

Conditions: Postoperative Pain

Summary: the aim of our study was to compare the effects of lomber epidural analgesia (lea), transversus abdominis plane (tap) block and local anesthetic infiltration (lai) on postoperative morphine consumption, time to first recue analgesic request, pain and patient satisfaction scores and side effects were compared in the patients undergoing major gynecologic/oncology lower abdominal surgery.

following faculty ethical committee approval and written informed consent, 81 patients were included in our prospective, randomized and double-blind study. patients were divided into 3 groups: lumbar epidural block (group e), tap block (group t), and wound infiltration (group i). demographic data, surgical characteristics, hemodynamic values, pain scores at rest and on movement, morphine consumption, additional analgesic requirement, side effects at 1, 2, 6, 12, 24, 36 and 48th hours after surgery, and patient satisfaction scores at 24 and 48th hours were recorded.

Eligibility criteria:
inclusion criteria: * asa i-ii, * between the age of 18-69, * undergoing major gynecological abdominal surgery under general anesthesia exclusion criteria: * lack of patient consent * asa \> iii * sensitivity or contraindication to study drugs * conditions in which epidural anesthesia is contraindicated * emergency and urgent surgery * inability to comprehend pain scale * any contraindication to the use of patient controlled analgesia (pca) device.

Keywords: epidural analgesia pain score morphine transversus abdominis plane block wound infiltration
quality of life improvements with cord blood plasma

Conditions: Aging

Summary: this study aims to look at whether human umbilical cord blood plasma (hucbp) is safe for intravascular (iv) administration; and whether it provides any reversal of frailty or other age-related biological measures.

participants that take part in this experimental treatment will receive six hucbp infusions over a six month period, with a final check-up occuring six months after the last infusion. blood samples will be collected before receiving each hucbp infusion, and at the last check-up. participants will also be asked to complete a medical questionnaire (sf 36) prior to the first infusion, and prior to each subsequent infusion. the medical questionnaire is four (4) pages in length and includes comprehensive questions about previous medical health and history. participation in the experimental treatment will involve monitoring by the principal doctor for a period of twelve months after the initial infusion of hucbp. a second infusion is planned for one month after the initial infusion, a third infusion is planned for two months after the initial infusion, a fourth infusion is planned for three months after the initial infusion, a fifth infusion is planned for four months after the initial infusion,and a sixth infusion is planned for five months after the initial infusion. participants will be asked to undergo the same blood tests and physical examinations performed at the time of the initial infusion at each of the five subsequent infusions (i.e. at one, two, three, four, and five months after the initial infusion). twelve months after the initial infusion participants will be asked to attend for final blood tests and physical examinations. there will be no hucbp infusion at the twelve-month visit. assessment criteria for the study include: (1) short form (36) health survey (sf 36); (2) biomarkers of inflammation, oxidative stress, and growth factors; (3) adrenal cortical hormone levels; (4) telomere length; (5) hand grip strength; (6) body fat measurement; (7) dna damage; and (8) overall safety of intravenous administration.

Eligibility criteria:
inclusion criteria: * aged 50 or older * be willing and able to participate during the 12 month research period * women - must be diagnosed with infertility or menopause exclusion criteria: * unable to perform tasks required for analysis of end points * history of being hospitalized dues to infectious disease, such as pneumonia, within the last year * recent and current use of immunosuppressive drugs or hiv patients * scheduled to receive organ transplant * dementia or clinically relevant cognitive impairment * participants of previous (within 1 month) or current clinical trials * severe heart and kidney failure * history of alcohol or drug abuse * known or suspected pregnancy * chronic hepatitis b or c * diagnosis of cancer within 5 year of the study, or the possibility to contract cancer * anticancer chemotherapy and radiation therapy
the biology of claudin 3 in primary human mammary epithelial cell culture

Conditions: Breast Cancer

Summary: the objective of the present study is to determine whether or not primary human mammary epithelial cells are competent for use in molecular studies of transepithelial electrophysiology focusing on the function of the tight junction protein claudin 3. human breast tissue will be removed from mastectomy specimens and used as a source to generate epithelial cells for study.


Eligibility criteria:
inclusion criteria: * subjects of this pilot study are limited to those female patients who are undergoing therapeutic or prophylactic mastectomy procedures conducted by the department of surgery at humc. exclusion criteria: * from within this population, no exclusion criteria shall be applied based on age, race, ethnicity, gender, hiv status, or menopause.

Keywords: claudin electrophysiology breast screening
clinical efficacy of in-situ thrombolysis in case of intraventricular haemorraghia by aneurysm rupture

Conditions: Aneurysm, Ruptured; Subarachnoid Hemorrhage

Summary: the purpose of this study is to determine the impact of in situ fibrinolysis on the mortality at 30 days in case of subarachnoid hemorrhage.


Eligibility criteria:
inclusion criteria: * subarachnoid hemorrhage by aneurysm rupture * severe intraventricular hemorraghia exclusion criteria: * pregnant women * hemostasis disturbance
observatoire des patients atteints de laminopathies et emerinopathies (observatory for patients with laminopathies and emerinopathies)

Conditions: Laminopathies; Emerinopathies

Summary: laminopathies and emerinopathies are complex group of rare disorders due to mutations in a-type lamins (lmna) and emerin (emd) genes. among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. remarkable progress has been made in the description of the clinical and genetic spectrum of these diseases since the 1990's. until now, precise phenotype/genotype relations remain elusive. as for several other neuromuscular disorders, apart from symptomatic treatments, there is currently no specific treatment to prevent or slow down the progression of the disease. the opale registry is a multicentre web-based registry dedicated to laminopathy and emerinopathy french patients. opale has been approved by ethical and regulatory authorities. its main inclusion criteria is the presence of a proven pathogenic lmna and/or emd gene mutation. the opale objectives are to provide a tool allowing detailed capture of patient genetic, neurological, cardiological, endocrinological and respiratory assessments, in order to allow i) precise disease natural history, ii) evaluation of different disease complication frequency and iii) identification of prognosis factors.


Eligibility criteria:
inclusion criteria: * presence of a proven pathogenic lmna and/or emd gene mutation * regular followup in france. * signed informed consent exclusion criteria: -refusal to sign an informed consent.

Keywords: lamin a/c lmna emerin emd
pharmacokinetics and pharmacdynamics of sildenafil

Conditions: Pulmonary Hypertension

Summary: the study is being done to investigate what happens to sildenafil in the body and how long it takes to get rid of this drug. understanding how long the drug stays in the body and how it is changed by the body will help doctors determine the best dose. we also want to learn how well the medicine works based on the size of the dose or amount in the bloodstream.

there is no data regarding sildenafil drug disposition in infants and children with pulmonary hypertension. sildenafil is used at the children's hospital of philadelphia for the treatment of pulmonary hypertension. patients receiving sildenafil as standard of care will be approached for consent.

Eligibility criteria:
inclusion criteria: * receive enteral sildenafil as standard of care * \> 28 days to \>18 years of age * informed consent/assent exclusion criteria: * parents/guardians and/or subjects who, in the opinion of the investigator, may be noncompliant with study schedules or procedures.

Keywords: sildenafil pediatrics
demonstrate the superiority of the immune response of adjuvanted influenza vaccine induced in an adult population

Conditions: Influenza

Summary: the study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed fluarix vaccine in subjects aged 50 years and above. a control group in younger adults aged 18 to 40 years was included.

this is a study to demonstrate the superiority of the immune response of adjuvanted influenza vaccine induced in an adult population.

Eligibility criteria:
inclusion criteria: * the subjects must be healthy adults 18-40 years or \>/= 50 years. exclusion criteria: * subjects will be excluded if they take/have taken chronically high doses of immunosuppressants or other immune modifying drugs within six months before vaccination, or immunoglobulins or blood products within three months before vaccination, or any investigational product within 30 days before vaccination, or a licensed vaccine within 2 (inactivated) to 4 (live) weeks before vaccination, if women are pregnant or lactating, or if subjects have acute clinically significant disease or an immunosuppressive/deficient condition, or have contra-indications to influenza vaccination.

Keywords: elderly improved vaccine influenza influenza disease
effect of pycnogenol® on adhd

Conditions: ADHD

Summary: this double blind, randomised controlled trial examines the effect of a commercially available nutritional supplement on behaviour of adhd patients, as well as on their physical and psychiatric co-morbidities, and level of oxidative stress and immune activity, as compared to placebo and standard pharmaceutical treatment for adhd.


Eligibility criteria:
inclusion criteria: * the patient is between 6-12 years old (both inclusive). * the patient satisfies the dsm-iv criteria for adhd or add. * the patient has a responsible caregiver who is able to provide information about the patient's functional status. * written informed consent is obtained from the patient and the legally accepted representative. exclusion criteria: * the patient does satisfy the dsm-iv for autism spectrum disorder. * the patient does have situational hyperactivity, pervasive developmental disorders, schizophrenia, other psychotic disorders such as mood or anxiety disorder, personality disorder as unsocial behaviour, personality change due to a general medical condition, mental retardation (iq \< 70), understimulating environments, conduct disorder, chorea and other dyskinesias. the patient does not have tics or tourette's syndrome, or personal or family history of psychotic disorder, bipolar illness, depression, or suicide attempt. * the patient does have any chronic medical disorder (diabetes, epilepsy or other seizure disorder, autoimmune disorder, gastrointestinal disorder, renal or cardiovascular disorders, etc.) or acute inflammatory disease. the patient does not have glaucoma, heart disease, heart rhythm disorder, high blood pressure, or peripheral vascular disease such as raynaud's syndrome. * the patient did use any of these medications during the 3 months before entering the study: clonidine, guanethidine, blood thinners (e.g. warfarin or coumadin), antidepressants (e.g. amitriptyline, citalopram, doxepin, fluoxetine, nortriptyline, paroxetine, sertraline), cold or allergy medicine that contains a decongestant, medications to treat high or low blood pressure, seizure medicine (e.g. phenobarbital, phenytoin, primidone), or diet pills. * the patient did take mao inhibitor (isocarboxazid, linezolid, phenelzine, rasagiline, selegiline or tranylcypromine) in the past 14 days. * the patient has any other contraindication for the use of methylphenidate. * the patient did use vitamin/mineral/herbal/omega-3 supplements or other any medication (psychoactive medication, antibiotics, anti-inflammatory drugs, melatonin, etc.) \> 1 week during the 3 months before inclusion.